Special Issue "The Immune Response in Patients after COVID-19 Vaccination"
Deadline for manuscript submissions: 31 May 2024 | Viewed by 1342
Interests: sarcoidosis; interstitial lung diseases; small airway diseases; interventional pulmonology; infectious diseases
Most healthy individuals have had one booster vaccination for COVID-19, while patients with immunocompromised conditions/treatments have had two booster doses. Evidence suggests that patients with such conditions (connective tissue diseases, idiopathic pulmonary fibrosis, subjects on intensive immunosuppressant treatments) exhibit a reduced response to vaccination.
There is also evidence that vaccines other than those designed specifically against COVID-19 may confer protection against this disease by the activation of innate immunity. Individuals with other diseases, such as sarcoidosis, are reportedly more vulnerable to COVID-19 infection, but results regarding outcome and mortality are contradictory. Guidelines suggest that vaccination in specific sub-populations should account for medication and the intensity of immunosuppressants administered.
Moreover, the evolution of new COVID-19 mutations and strains further aggravate the uncertainty about the effectiveness of current vaccines’ immune response.
The purpose of this Special Issue is to investigate the immunization response, vaccination status, and clinical outcomes in immunocompetent and immunocompromised adults, especially those with sarcoidosis, other interstitial lung diseases or other immunosuppressant statuses, from an immunological or clinical perspective. We look forward to your contributions to this Special Issue, which we hope will contribute to the knowledge regarding this emerging landscape.
Dr. Ilias C. Papanikolaou
Dr. Nadera J. Sweiss
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune response
- interstitial lung diseases